Article
TP53 Mutations Unfavorably Impact the Outcomes of Myelofibrosis Patients with or Without Hematopoietic Stem Cell Transplantation: A Single-Center Study and Meta-Analysis.
International journal of molecular sciences - 25 May 2026
Frioni Filippo, Giammarco Sabrina, Ceglie Sara, Betti Silvia, Ramundo Francesco, Marra John, Rossi Monica, Fosso Federica, Minnella Gessica, Metafuni Elisabetta, Sorà Federica, Bacigalupo Andrea, Sica Simona, Rossi Elena, De Stefano Valerio, Chiusolo Patrizia
Abstract excerpt
TP53 mutation is known to be a poor prognostic factor in many hematologic malignancies, but it is not included in any Myelofibrosis-specific prognostic score. Recently, studies have shown that TP53 mutation may negatively impact the outcomes of patients with Myelofibrosis, including those undergoing hematopoietic stem cell transplantation. In this study, we aimed to analyze the impact of TP53 mutation on the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.